Using a proprietary platform that mines genomics data, Rgenta Therapeutics designs small-molecule glues to modulate interactions among the spliceosome, regulatory proteins, and RNAs. This approach unlocks the therapeutic potential of historically undruggable targets in human diseases. The company's compound library accounts for cell type-specific target regulation and predicts the biological consequences of target modulation, opening up opportunities for drug development in oncology and neurological disorders. Founded in 2018 and headquartered in Cambridge, Massachusetts, Rgenta Therapeutics is an operator of a data-driven mRNA target identification platform.